Ensign Peak Advisors’s ALX Oncology ALXO Stock Holding History

Ensign Peak Advisors’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$941K	Sell	677,255 -133,042	-16%	-$257K	﹤0.01%	814
2026 Q2	$1.68M	Sell	810,297 -140,253	-15%	-$251K	﹤0.01%	775
2026 Q1	$1.91M	Buy	+950,550	New	+$1.81M	﹤0.01%	719
2022 Q3	–	Sell	-1,350	Closed	-$11K	–	2311
2022 Q2	$11K	Sell	1,350 -126,082	-99%	-$1.37M	﹤0.01%	2143
2022 Q1	$2.15M	Hold	127,432	–	–	﹤0.01%	852
2021 Q4	$2.74M	Sell	127,432 -218,052	-63%	-$9.41M	0.01%	849
2021 Q3	$25.5M	Sell	345,484 -31,381	-8%	-$2.09M	0.05%	275
2021 Q2	$20.6M	Buy	376,865 +40,566	+12%	+$2.43M	0.04%	313
2021 Q1	$24.8M	Buy	336,299 +309,255	+1,144%	+$24.3M	0.05%	276
2020 Q4	$2.33M	Buy	+27,044	New	+$1.63M	0.01%	972

Other funds holding ALXO

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Walleye Capital New York $109B AUM 29.28% 1-Year Est. Return

Ensign Peak Advisors's ALXO Position: Q3 2026 in Review

Ensign Peak Advisors reduced its ALX Oncology (ALXO) stake by 16% in Q3 2026, selling an estimated $257K and leaving 677,255 shares worth $941K. The position accounts for ﹤0.01% of the portfolio, ranked #814.

Ensign Peak Advisors first reported a position in ALXO in Q4 2020 and has held it in 10 quarters since. The position peaked at $25.5M in Q3 2021. 65 funds tracked by Wall St. Rank hold ALXO as of Q3 2026.

Ensign Peak Advisors held 677,255 shares of ALX Oncology worth $941K as of Q3 2026.
Ensign Peak Advisors sold 133,042 ALX Oncology shares in Q3 2026, an estimated $257K.
ALX Oncology made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q3 2026, its #814 holding.
Ensign Peak Advisors first reported a position in ALX Oncology in Q4 2020 and has held it in 10 quarters since.
Ensign Peak Advisors's ALX Oncology position peaked at $25.5M in Q3 2021.
65 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2026.

Based on Ensign Peak Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.